ArthNow Logo
ArthNow
•5 min read•
✦Reported by Livemint

IPO Lock-in Expiry: $35 billion in shares set to unlock across 116 companies; Jio, NSE, Zetwerk in focus

IPO Lock-in Expiry: $35 billion in shares set to unlock across 116 companies; Jio, NSE, Zetwerk in focus
Source: Livemint

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓Shares worth $35 billion will unlock across 116 companies between 9 November 2026 and 26 February 2027.
  • ✓Major firms like Jio Platforms, NSE, and Zetwerk are in focus.
  • ✓While many shares become eligible for trading, experts said that promoters may keep their stakes, so selling pressure might not be high.

Story at a Glance

Category
Indian Markets
Reported By
Livemint
Reading Speed
5 Minute(s)
Market Focus
India Economy

The upcoming IPO lock-in expiries could put nearly $35 billion worth of shares on investors' radar over the next few months, as pre-listing shareholder lock-in periods across 116 companies are set to end between 9 November 2026 and 26 February 2027.

The list includes several prominent recent listings, such as Jio Platforms, Zetwerk Manufacturing Business, Shiprocket, Milky Mist Dairy Food, SBI Funds Management and the National Stock Exchange of India (NSE). However, unlocking shares does not necessarily mean they will be sold in the market. A substantial portion of the shares is held by promoters and their groups, who may continue to hold their stakes.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

Livemint

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.